IRIS International, Inc. Unveils NADiA(R) ProsVue(TM) at the American Urological Association Annual Meeting, May 19-24, 2012

Published: May 21, 2012

CHATSWORTH, Calif., May 21, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, today announced that the Iris Personalized Medicine group is unveiling its novel prostate cancer system, NADiA® ProsVue™ at the American Urological Association (AUA) Annual Meeting in Atlanta. NADiA ProsVue, a prognostic prostate cancer test, will be showcased at the Iris Personalized Medicine booth #2530 where urologists and healthcare professionals can learn more about the test's innovative Immuno-PCR technology and clinical benefit.

Back to news